NICE Rejects Pierre Fabre’s Javlor, Citing Basic Evidence Errors
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE has turned down Pierre Fabre’s Javlor for cancer of the urothelial tract, saying the French company’s basic trial structure did not meet its requirements.